Trial Search Results

A Study of H3B-8800 (RVT-2001) in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

The main purpose of this study is to determine the safety of the study drug H3B-8800 in humans and to understand better how the study drug works in your type of cancer. The study will also collect information on how long you live and the side effects that you may experience during the study.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Hemavant Sciences GmbH


  • Drug: H3B-8800 (RVT-2001)


Phase 1


Inclusion Criteria:

   1. Confirmed diagnosis of MDS, CMML, or AML.

   For the MDS Expansion cohort, participants must be lower-risk MDS, defined as low or
   intermediate-1 risk categorization per International Prognostic Scoring System (IPSS)
   criteria that carries a missense SF3B1 mutation.

   For the Dose Optimization cohort, participants must be transfusion-dependent,
   lower-risk MDS, defined as very-low to intermediate risk categorization per IPSS-R
   criteria that carries a missense SF3B1 mutation.

   2. Participants must meet the following criteria relevant to their specific diagnosis:

   A. Participants with higher-risk MDS/CMML must be intolerant of hypomethylating agents
   (HMAs) or not have responded to 4 treatment cycles of decitabine or 6 treatment cycles
   of azacitidine, or must have progressed at any point after initiation of an HMA.

   B. For the Dose Escalation portion, participants with lower-risk MDS/CMML must be
   transfusion-dependent for red blood cells or platelets.

   For the MDS expansion cohort, lower risk MDS participants must be RBC transfusion
   dependent according to IWG 2006 criteria and must also have failed erythropoiesis
   stimulating agents (ESA) or have serum erythropoietin (EPO) levels greater than (>)
   500 units per liter (U/L).

   C. For the Dose Optimization cohort, lower-risk MDS participants must be RBC
   transfusion-dependent at baseline defined as ≥3 RBC units (concentrates) in 16-weeks
   in at least 2 transfusion episodes prior to the first dose of H3B-8800 (RVT-2001) and
   must also have failed ESA or have serum EPO levels > 500 U/L. Any ESA use should be
   discontinued ≥6 weeks prior to enrollment.

   D. Participants with AML must either refuse or not be considered candidates for
   intensive induction chemotherapy using consensus criteria for defining such

   E. Participants with CMML must have been treated with at least one prior therapy
   (hydroxyurea or a hypomethylating agent [HMA]).

   3. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.

   4. For MDS expansion and Dose optimization cohorts - absolute neutrophil count (ANC)
   greater than or equal to (>=) 500/ microliter (mcL) (0.5*10^9/L).

   5. For expansion and Dose optimization cohorts- platelet count >50,000/mcL (50*10^9/L).

   6. For Dose-optimization cohort: No prior HMA or lenalidomide in participants with
   lower-risk MDS.

   7. Adequate baseline organ function.

Exclusion Criteria:

   1. Diagnosis of a core binding factor leukemia (t(8;21), t(16;16) or inv(16)). Diagnosis
   of acute promyelocytic leukemia (t(15;17))

   2. Participants are deemed candidate for hematopoietic stem cell transplants at the time
   of enrollment (for AML participants only).

   3. Known prior or current retinal or optic nerve disease (example, Retinitis Pigmentosa,
   diabetic retinopathy, optic neuritis) not stable for at least 6 months.

   4. History of clinically significant, uncorrected vitamin B12 or folate deficiency.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Anousheh Afjei